May 2008
Volume 49, Issue 13
Free
ARVO Annual Meeting Abstract  |   May 2008
Expression of Sirt1 in Retinoblastoma: A Potential Therapeutic Target
Author Affiliations & Notes
  • R. N. Vianna
    Ophthalmology, Fluminense Federal University, Niteroi, Brazil
    The Henry C. Witelson Ocular Pathology Laboratory, McGill University, Montreal, Quebec, Canada
  • B. F. Fernandes
    The Henry C. Witelson Ocular Pathology Laboratory, McGill University, Montreal, Quebec, Canada
  • C. Martins
    The Henry C. Witelson Ocular Pathology Laboratory, McGill University, Montreal, Quebec, Canada
  • E. Antecka
    The Henry C. Witelson Ocular Pathology Laboratory, McGill University, Montreal, Quebec, Canada
  • M. E. Orellana
    The Henry C. Witelson Ocular Pathology Laboratory, McGill University, Montreal, Quebec, Canada
  • M. N. Burnier, Jr.
    The Henry C. Witelson Ocular Pathology Laboratory, McGill University, Montreal, Quebec, Canada
  • Footnotes
    Commercial Relationships  R.N. Vianna, None; B.F. Fernandes, None; C. Martins, None; E. Antecka, None; M.E. Orellana, None; M.N. Burnier, None.
  • Footnotes
    Support  None.
Investigative Ophthalmology & Visual Science May 2008, Vol.49, 24. doi:https://doi.org/
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      R. N. Vianna, B. F. Fernandes, C. Martins, E. Antecka, M. E. Orellana, M. N. Burnier, Jr.; Expression of Sirt1 in Retinoblastoma: A Potential Therapeutic Target. Invest. Ophthalmol. Vis. Sci. 2008;49(13):24. doi: https://doi.org/.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: : SIRT1 is a histone deacetylase protein that regulates cell survival. Recent papers have reported higher endogenous levels of SIRT1 expression in human breast cancer, human colon cancer, human non-melanoma skin cancers, mouse and human prostate cancer, and mouse pulmonary adenocarcinoma. Because SIRT1 may function as a tumor promoter it should be considered as a potential therapeutic target. This study aims to determine the immunoexpression of SIRT1 in retinoblastoma and correlate this expression with histopathological prognostic factors.

Methods: : Forty-five paraffin-embedded retinobalstomas were collected from the Henry C. Witelson Ocular Pathology Registry, McGill University, Montreal, Canada. The SIRT1 immunostaining was used according to the protocol provided by Abcam Inc. Immunoreactivity was correlated with the presence or absence of invasion into the choroid and optic nerve and the degree of tumor differentiation. Two independent ophthalmic pathologists reviewed all the microslides.

Results: : Seven (15.5%) slides were excluded from analysis due to insufficient viable tumor material. Overall, SIRT1 expression was identified in 34/38 (89.5%) specimens analyzed. Three (42.8%) out of 7 tumors without choroidal and/or optic nerve invasion were positive for SIRT1. On the other hand, SIRT1 expression was seen in 30 (96.8%) of the 31 tumors with extra-retinal invasion (p<0.002), 29 (96.7%) of 30 specimens with choroidal involvement (p<0.005), and in all specimens with optic nerve involvement (p<0.02). Ten (77%) of 13 moderate or well differentiated tumors and 24 (96%) of 25 undifferentiated tumors displayed positivity for SIRT1 (p<0.07).

Conclusions: : Most of the retinoblastoma specimens in this study expressed SIRT1. The expression of SIRT1 strongly correlated with histopathological features of worse prognosis including optic nerve and choroidal invasion. Our results also suggest that SIRT1 should be considered as a potential therapeutic target for retinoblastoma.

Keywords: retinoblastoma 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×